The next generation of OA pain management
Fast acting, long lasting, non-opioid, and backed by robust clinical data. For patients suffering from the chronic pain associated with OA of the knee.
About osteoarthritis
Osteoarthritis (OA) is a common, chronic, progressive disease that slowly deteriorates the joint. It is characterized by the loss of cartilage and a reduction in the amount of natural hyaluronic acid (HA) normally found in a healthy joint.
Is Cingal right for you?
Anika’s Cingal is the only next-generation non-opioid OA pain management product that is registered and approved for sale in 35+ countries.
Next generation, non-opioid OA pain management
First and only approved* combination hyaluronic acid (HA) plus steroid treatment for the pain of osteoarthritis
fast acting pain relief
Steroid provides rapid short-term pain relief within days of injection1
long lasting pain relief
HA viscosupplement provides long lasting pain relief through 6 months1
convenient single-injection treatment
Simple one injection procedure that can be done in the convenience of a physician’s office
Natural Solution
Highly concentrated, non-animal based HA produced from bacterial fermentation
Safe and Effective
Strong safety profile in both an initial injection1 as well as a repeat injection2
Clinically Proven
Unprecedented rapid and long lasting knee pain relief demonstrated across three Phase III Cingal clinical trials3
Cingal® delivers fast acting and long lasting relief from the pain of osteoarthritis. Cingal is helping patients all over the world to once again enjoy daily physical activities with reduced pain.
Fast Acting. Long Lasting.
CINGAL IS CLINICALLY PROVEN TO DELIVER STATISTICALLY SIGNIFICANT KNEE PAIN RELIEF, PROVIDING FASTER PAIN RELIEF COMPARED TO HA ALONE, AND DEMONSTRATING SUPERIOR LONG LASTING PAIN RELIEF COMPARED TO SALINE (CONTROL).1
Only Cingal
For patients who demand rapid and long-lasting relief from chronic knee pain associated with OA, there is one treatment that surpasses all others.
*CINGAL is CE Mark approved and Health Canada approved.
1. CINGAL 13-01, a randomized, double-blind, placebo-controlled, active comparator Phase III study. Anika Therapeutics, Inc.: study sponsor, Dr. Laszlo Hangody: global principal investigator, SynteractHCR: CRO.
2. CINGAL 13-02, an open-label, follow-on study to Cingal 13-01. Anika Therapeutics, Inc.: study sponsor, Dr. Laszlo Hangody: global principal investigator, SynteractHCR: CRO.
3. Data on file, Anika Therapeutics, Inc.